LBF18107PG01: Difference between revisions

No edit summary
No edit summary
 
(16 intermediate revisions by the same user not shown)
Line 6: Line 6:
|LipidBank=XPR1821
|LipidBank=XPR1821
|LipidMaps=LMFA03010089
|LipidMaps=LMFA03010089
|SysName=5- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -4-oxopentanoic acid
|SysName=5- [ (3R,5S) -Dihydroxy-2R- (3S-hydroxy-trans-1-octenyl) cyclopentan-1R-yl ] -4-oxopentanoic acid
|Common Name=&&2,3-dinor-6-ketoprostaglandin F_1alpha&&5- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -4-oxopentanoic acid&&
|Common Name=&&2,3-dinor-6-keto Prostaglandin F_1 alpha&&5- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -4-oxopentanoic acid&&
|Reflactive=[<FONT FACE="Symbol">a</FONT>]<SUP><FONT SIZE=-1>2</FONT></SUP><SUP><FONT SIZE=-1>0</FONT></SUP><SUP><FONT SIZE=-1>.</FONT></SUP><SUP><FONT SIZE=-1>2</FONT></SUP><SUB><FONT SIZE=-1>D</FONT></SUB>= +16.9° (C=1.76 CHLOROFORM, measured after 24 hours at 20°C)  
|Optical=[ alpha ]^{20.2}_D = +16.9° (C=1.76 CHLOROFORM, measured after 24 hours at 20°C) <!--1060-->
|Solubility=METHANOL [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]]
|Solubility=METHANOL [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]]
|Mass Spectra=METHOXIME TRI-TMS ETHER METHYL ESTER ; m/e 601(M<SUP><FONT SIZE=-1>+</FONT></SUP>), 586, 570, 530, 511, 496, 480, 440, 421, 390, 350, 300, 294, 263, 217, 205, 191, 73 [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]]
|Mass Spectra=METHOXIME TRI-TMS ETHER METHYL ESTER ; m/e 601(M^+ ), 586, 570, 530, 511, 496, 480, 440, 421, 390, 350, 300, 294, 263, 217, 205, 191, 73 [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]]
|Source=When prostaglandin I2 or its non-enzymatic degradation product (6-keto-prostaglandin F1<FONT FACE="Symbol">a</FONT>) was infused into man, a major urinary metbolite was 2,3-dinor-6-keto-prostaglandin F1<FONT FACE="Symbol">a</FONT>, a <FONT FACE="Symbol">b</FONT>-oxidation product [[Reference:Needleman_P:Turk_J:Jakschik_BA:Morrison_AR:Lefkowith_JB:,Annu. Rev. Biochem.,1986,55,69|{{RelationTable/GetFirstAuthor|Reference:Needleman_P:Turk_J:Jakschik_BA:Morrison_AR:Lefkowith_JB:,Annu. Rev. Biochem.,1986,55,69}}]];>.
|Source=When prostaglandin I2 or its non-enzymatic degradation product (6-keto-prostaglandin F1 alpha ) was infused into man, a major urinary metbolite was 2,3-dinor-6-keto-prostaglandin F1 alpha , a beta -oxidation product [[Reference:Needleman_P:Turk_J:Jakschik_BA:Morrison_AR:Lefkowith_JB:,Annu. Rev. Biochem.,1986,55,69|{{RelationTable/GetFirstAuthor|Reference:Needleman_P:Turk_J:Jakschik_BA:Morrison_AR:Lefkowith_JB:,Annu. Rev. Biochem.,1986,55,69}}]].
|Chemical Synthesis= {{Image200|LBF18107PG01FT0001.gif}}
|Chemical Synthesis=<!--1060--> {{Image200|LBF18107PG01FT0001.gif}}
|Metabolism=
|Metabolism=
|Symbol=2,3-DINOR-6-KETO-PGF1 alpha
}}
}}


{{Lipid/Footer}}
{{Lipid/Footer}}

Latest revision as of 06:40, 21 October 2010

LipidBank Top
(トップ) 		Fatty acid
(脂肪酸) 		Glycerolipid
(グリセロ脂質) 		Sphingolipid
(スフィンゴ脂質) 		Journals
(雑誌一覧) 		How to edit
(ページの書き方)


Upper classes: LB LBF



IDs and Links
LipidBank XPR1821
LipidMaps LMFA03010089
CAS
KEGG {{{KEGG}}}
KNApSAcK {{{KNApSAcK}}}
mol LBF18107PG01
2,3-dinor-6-keto Prostaglandin F1α
LBF18107PG01.png
Structural Information
5- [ (3R,5S) -Dihydroxy-2R- (3S-hydroxy-trans-1-octenyl) cyclopentan-1R-yl ] -4-oxopentanoic acid
  • 2,3-dinor-6-keto Prostaglandin F1α
  • 5- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -4-oxopentanoic acid
 2,3-DINOR-6-KETO-PGF1 alpha
Formula C18H30O6
Exact Mass 342.204238692
Average Mass 342.42719999999997
SMILES [C@@H]([C@@H](CC(=O)CCC(O)=O)1)(C=C[C@H](O)CCCCC)[C@H](O)C[C@@H]1O
Physicochemical Information
[ α ]20.2
D     = +16.9° (C=1.76 CHLOROFORM, measured after 24 hours at 20°C)
METHANOL Pace-Asciak_CR et al.
When prostaglandin I2 or its non-enzymatic degradation product (6-keto-prostaglandin F1 alpha ) was infused into man, a major urinary metbolite was 2,3-dinor-6-keto-prostaglandin F1 alpha , a beta -oxidation product Needleman_P et al..

LBF18107PG01FT0001.gif
Spectral Information
Mass Spectra METHOXIME TRI-TMS ETHER METHYL ESTER ; m/e 601(M+), 586, 570, 530, 511, 496, 480, 440, 421, 390, 350, 300, 294, 263, 217, 205, 191, 73 Pace-Asciak_CR et al.
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF18107PG01 See above. Needleman_P et al. 1986
n.a. LBF18107PG01 See above. Pace-Asciak_CR et al. 1977


Retrieved from "http://lipidbank.jp/mediawiki/index.php?title=LBF18107PG01&oldid=48667"